{"id":"https://openalex.org/W3140930637","doi":"https://doi.org/10.1002/cbic.202100047","title":"Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule","display_name":"Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule","publication_year":2021,"publication_date":"2021-04-10","ids":{"openalex":"https://openalex.org/W3140930637","doi":"https://doi.org/10.1002/cbic.202100047","mag":"3140930637","pmid":"https://pubmed.ncbi.nlm.nih.gov/33838082"},"language":"en","primary_location":{"id":"doi:10.1002/cbic.202100047","doi":"https://doi.org/10.1002/cbic.202100047","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cbic.202100047","pdf_url":null,"source":{"id":"https://openalex.org/S154285657","display_name":"ChemBioChem","issn_l":"1439-4227","issn":["1439-4227","1439-7633"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ChemBioChem","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041910319","display_name":"Tim J. Wigle","orcid":"https://orcid.org/0000-0002-7010-6738","observed_orcids":["https://orcid.org/0000-0002-7010-6738"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Tim J. Wigle","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":"https://orcid.org/0000-0002-7010-6738","affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101526663","display_name":"Yue Ren","orcid":"https://orcid.org/0000-0001-6199-1715","observed_orcids":["https://orcid.org/0000-0001-6199-1715"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yue Ren","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060688708","display_name":"Jennifer R. Molina","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Molina","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011185745","display_name":"Danielle J. Blackwell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle J. Blackwell","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048268356","display_name":"Laurie B. Schenkel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laurie B. Schenkel","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059082950","display_name":"Kerren K. Swinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerren K. Swinger","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035990195","display_name":"Kristy G. Kuplast-Barr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristy Kuplast\u2010Barr","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064617551","display_name":"Christina R. Majer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christina R. Majer","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045602223","display_name":"W. David Church","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. David Church","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002269523","display_name":"Alvin Ziying Lu","orcid":"https://orcid.org/0000-0003-2353-848X","observed_orcids":["https://orcid.org/0000-0003-2353-848X"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alvin Z. Lu","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059067238","display_name":"Jason Mo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Mo","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035259692","display_name":"Ryan Abo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Abo","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006441142","display_name":"Anne E. Cheung","orcid":"https://orcid.org/0000-0001-6041-692X","observed_orcids":["https://orcid.org/0000-0001-6041-692X"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Cheung","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022616937","display_name":"Bryan W. Dorsey","orcid":"https://orcid.org/0000-0002-6783-3547","observed_orcids":["https://orcid.org/0000-0002-6783-3547"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan W. Dorsey","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040454293","display_name":"Mario Niepel","orcid":"https://orcid.org/0000-0003-1415-6295","observed_orcids":["https://orcid.org/0000-0003-1415-6295"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mario Niepel","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017302969","display_name":"Nicholas R. Perl","orcid":"https://orcid.org/0000-0001-6209-4936","observed_orcids":["https://orcid.org/0000-0001-6209-4936"]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas R. Perl","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054565788","display_name":"Melissa M. Vasbinder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa M. Vasbinder","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078823930","display_name":"Heike Keilhack","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heike Keilhack","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041960498","display_name":"Kevin W. Kuntz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158382","display_name":"Ribon Therapeutics (United States)","ror":"https://ror.org/05azc9n12","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin W. Kuntz","raw_affiliation_strings":["Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ribon Therapeutics, 35 Cambridgepark Dr., Suite 300, Cambridge, MA 02140 USA","institution_ids":["https://openalex.org/I4210158382"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5041910319"],"corresponding_institution_ids":["https://openalex.org/I4210158382"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.911,"has_fulltext":false,"cited_by_count":18,"citation_normalized_percentile":{"value":0.70146564,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":97},"biblio":{"volume":"22","issue":"12","first_page":"2107","last_page":"2110"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.01140000019222498,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp14","display_name":"PARP14","score":1.0},{"id":"https://openalex.org/keywords/protein-degradation","display_name":"protein degradation","score":0.5799999833106995},{"id":"https://openalex.org/keywords/cereblon","display_name":"cereblon","score":0.8410000205039978},{"id":"https://openalex.org/keywords/ubiquitination","display_name":"ubiquitination","score":0.8640000224113464},{"id":"https://openalex.org/keywords/nad-binding-site","display_name":"NAD+ binding site","score":0.7379999756813049},{"id":"https://openalex.org/keywords/catalytic-inhibitors","display_name":"catalytic inhibitors","score":0.7459999918937683},{"id":"https://openalex.org/keywords/interferon-stimulated-genes","display_name":"interferon-stimulated genes","score":0.7609999775886536},{"id":"https://openalex.org/keywords/tumor-associated-macrophages","display_name":"tumor-associated macrophages","score":0.875},{"id":"https://openalex.org/keywords/macrophage-polarization","display_name":"macrophage polarization","score":0.8199999928474426},{"id":"https://openalex.org/keywords/interferon-gamma-signaling","display_name":"interferon-gamma signaling","score":0.7009999752044678},{"id":"https://openalex.org/keywords/il-4-signaling","display_name":"IL-4 signaling","score":0.9850000143051147},{"id":"https://openalex.org/keywords/poly-adp-ribose","display_name":"poly(ADP-ribose)","score":0.8259999752044678},{"id":"https://openalex.org/keywords/rna-recognition-motif","display_name":"RNA recognition motif","score":0.5580000281333923},{"id":"https://openalex.org/keywords/tumor-immunology","display_name":"tumor immunology","score":0.4309999942779541}],"concepts":[{"id":"https://openalex.org/C161624437","wikidata":"https://www.wikidata.org/wiki/Q1988322","display_name":"Small molecule","level":2,"score":0.605317234992981},{"id":"https://openalex.org/C2779461342","wikidata":"https://www.wikidata.org/wiki/Q59817493","display_name":"Ribose","level":3,"score":0.5473043322563171},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.5213407278060913},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.5046769380569458},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.4961105287075043},{"id":"https://openalex.org/C75520062","wikidata":"https://www.wikidata.org/wiki/Q15321392","display_name":"NAD+ kinase","level":3,"score":0.48019134998321533},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.46292683482170105},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4010283350944519},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3445059061050415},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.33803510665893555},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.14709380269050598}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008264","descriptor_name":"Macrophages","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008264","descriptor_name":"Macrophages","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011065","descriptor_name":"Poly(ADP-ribose) Polymerases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054852","descriptor_name":"Small Molecule Libraries","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D054852","descriptor_name":"Small Molecule Libraries","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D054852","descriptor_name":"Small Molecule Libraries","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cbic.202100047","doi":"https://doi.org/10.1002/cbic.202100047","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cbic.202100047","pdf_url":null,"source":{"id":"https://openalex.org/S154285657","display_name":"ChemBioChem","issn_l":"1439-4227","issn":["1439-4227","1439-7633"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ChemBioChem","raw_type":"journal-article"},{"id":"pmid:33838082","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33838082","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Chembiochem : a European journal of chemical biology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W2010445535","https://openalex.org/W2015264243","https://openalex.org/W2017813215","https://openalex.org/W2088689845","https://openalex.org/W2096529411","https://openalex.org/W2166617377","https://openalex.org/W2479314877","https://openalex.org/W2560733654","https://openalex.org/W2598716813","https://openalex.org/W2609026834","https://openalex.org/W2761766456","https://openalex.org/W2792846855","https://openalex.org/W2799860862","https://openalex.org/W2903291787","https://openalex.org/W2912114516","https://openalex.org/W2981857847","https://openalex.org/W2995386570","https://openalex.org/W2996380129","https://openalex.org/W3042576047","https://openalex.org/W3048940337","https://openalex.org/W3086905229","https://openalex.org/W4234242871","https://openalex.org/W6789445582"],"related_works":["https://openalex.org/W3180628366","https://openalex.org/W3083112850","https://openalex.org/W3135517426","https://openalex.org/W7155354051","https://openalex.org/W2889240712","https://openalex.org/W4392791513","https://openalex.org/W2914328135","https://openalex.org/W4393162575","https://openalex.org/W2977832830","https://openalex.org/W2893360176"],"abstract_inverted_index":{"Abstract":[0],"PARP14":[1,31,51,79,128],"is":[2,7,32,94],"an":[3],"interferon\u2010stimulated":[4],"gene":[5,88],"that":[6,37,129],"overexpressed":[8],"in":[9,69,90,105,131],"multiple":[10],"tumor":[11],"types,":[12],"influencing":[13],"pro\u2010tumor":[14,87],"macrophage":[15],"polarization":[16],"as":[17,19],"well":[18],"suppressing":[20],"the":[21,44,99,132],"antitumor":[22],"inflammation":[23],"response":[24],"by":[25],"modulating":[26],"IFN\u2010\u03b3":[27],"and":[28,56,66,108,136,142],"IL\u20104":[29,85],"signaling.":[30],"a":[33,39,57,117,124],"203":[34],"kDa":[35],"protein":[36],"possesses":[38],"catalytic":[40,125],"domain":[41,59],"responsible":[42],"for":[43,64,146],"transfer":[45],"of":[46,78,127],"mono\u2010ADP\u2010ribose":[47,65],"to":[48,71,83,139],"its":[49],"substrates.":[50],"also":[52],"contains":[53],"three":[54],"macrodomains":[55],"WWE":[58],"which":[60],"are":[61],"binding":[62],"modules":[63],"poly\u2010ADP\u2010ribose,":[67],"respectively,":[68],"addition":[70],"two":[72],"RNA":[73],"recognition":[74,102],"motifs.":[75],"Catalytic":[76],"inhibitors":[77],"have":[80,115],"been":[81],"shown":[82],"reverse":[84],"driven":[86],"expression":[89],"macrophages,":[91],"however":[92],"it":[93,141,145],"not":[95],"clear":[96],"what":[97],"roles":[98],"non\u2010enzymatic":[100],"biomolecular":[101],"motifs":[103],"play":[104],"PARP14\u2010driven":[106],"immunology":[107],"inflammation.":[109],"To":[110],"further":[111],"understand":[112],"this,":[113],"we":[114],"discovered":[116],"heterobifunctional":[118],"small":[119],"molecule":[120],"designed":[121],"based":[122],"on":[123],"inhibitor":[126],"binds":[130],"enzyme's":[133],"NAD+\u2010binding":[134],"site":[135],"recruits":[137],"cereblon":[138],"ubiquitinate":[140],"selectively":[143],"target":[144],"degradation.":[147]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-04-13T00:00:00"}